Anne Burrell died by suicide, medical examiner finds
Popular Food Network star and celebrity chef Anne Burrell's death has been ruled a suicide, according to authorities.
The Office of the Chief Medical Examiner in New York City confirmed to CNN on Thursday that Burrell died by suicide and that her cause of death is acute intoxication due to the combined effects of diphenhydramine, ethanol, cetirizine and amphetamine.
Burrell, a chef and beloved fixture on the Food Network, died last month at her home in New York. She was 55.
A spokesperson for the New York Police Department told CNN at the time that officers responded to Burrell's home in Brooklyn, where they 'observed a 55-year-old female unconscious and unresponsive.'
'EMS responded and pronounced the female deceased at the scene,' police said.
In a statement provided by the Food Network at the time, Burrell's family said that her 'light radiated far beyond those she knew, touching millions across the world.'
'Though she is no longer with us, her warmth, spirit, and boundless love remain eternal,' their statement added.
A Food Network spokesperson added: 'Anne was a remarkable person and culinary talent – teaching, competing and always sharing the importance of food in her life and the joy that a delicious meal can bring. Our thoughts are with Anne's family, friends and fans during this time of tremendous loss.'
Burrell had a storied history as a television personality and chef but was best known as one of the Food Network's most popular stars, appearing in several of the network's series including 'Worst Cooks in America,' 'Iron Chef America,' 'Chef Wanted with Anne Burell' and 'The Best Thing I Ever Ate,' among many others, over the years.
This is a developing story.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
29 minutes ago
- Medscape
Alcohol-Related Liver Disease Increases Sharply
Significant liver fibrosis associated with heavy alcohol use rose more than twofold over roughly the past two decades in the US despite alcohol use rates holding steady, which might be explained by risk factors for alcohol-related liver injury in the population, researchers said. Those most likely to be heavy drinkers are women, adults aged 45 years or older, those living in poverty, and those with metabolic syndrome, the data showed. 'Alcohol-related liver disease is the main cause of liver-related death, and these results are a major wake-up call to the dangers of drinking,' lead investigator Brian Lee, MD, MAS, hepatologist and liver transplant specialist with Keck Medicine of University of Southern California, Los Angeles, said in a statement. The study was published online on July 23 in Clinical Gastroenterology and Hepatology . Call for Increased Awareness To gauge trends in advanced alcohol-related liver disease among heavy drinkers, Lee and colleagues mined data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999-2020. The primary outcome was a high Fibrosis-4 (FIB-4) score (FIB-4 > 2.67 for those aged 65 years or younger and > 3.25 for those older than 65 years), which has previously been linked to a 25-fold higher risk for liver-related death. People with hepatitis B or C were excluded. Among 44,628 adults, 2474 were heavy drinkers — defined as at least 20 g/d for women and 30 g/d for men in the prior year. Among heavy drinkers, the prevalence of high FIB-4 — a marker of advanced liver scarring — increased more than twofold over time, from 1.8% in 1999-2004 to 4.3% in 2013-2020, vs an increase of 0.8%-1.4% among non-heavy drinkers. Notably, average alcohol intake stayed the same during the study period, the researchers said. Among heavy drinkers, the prevalence of metabolic syndrome rose from 26.4% in 1999-2004 to 37.6% in 2013-2020, the mean age increased, and a greater proportion was women or living in poverty — factors that can amplify susceptibility to alcohol's liver effects. Supplementary analyses restricting the cohort to adults aged 35-65 years or to pre-pandemic years (1999-2018) confirmed the same upward trends, with significant liver scarring tripling over 20 years. Limitations cited by the authors include the cross-sectional design of NHANES and reliance on self-reported alcohol intake, which can't capture fluctuations over time, and the use of FIB-4 as a surrogate for liver disease. Collectively, the data suggest that increasing morbidity and mortality due to alcohol-related liver disease 'may be related to a population more sensitized to the alcohol-related effects in the liver due to increased baseline risk factors,' the researchers wrote. The findings provide impetus for 'urgent awareness' of the contemporaneous risk for alcohol-related liver disease with heavy drinking and interventions to screen and treat risk factors, they added.
Bloomberg
an hour ago
- Bloomberg
How US Health Insurers Got 2025 Numbers So Wrong
Hi, it's John in New York. In the last few months, I've watched a set of insurers that reliably grew profits for years collapse with spectacular speed. We try to unpack what's going on with US health insurance below. But first ... Every year, number crunchers at US health insurance companies look at their enrolled populations and calculate how many of them will break their arms, require a heart stent or be diagnosed with cancer. They use these figures to determine how much to charge in premiums to be able to cover patients' medical issues and still make a profit.
Medscape
an hour ago
- Medscape
Nontargeted Hepatitis C Screening Yields More Diagnoses
TOPLINE: Nontargeted hepatitis C virus (HCV) screening in emergency departments (EDs) was superior to targeted screening for identifying new HCV infections in a prospective randomized screening trial. However, only a small proportion of diagnosed patients achieved sustained virologic response at 12 weeks, emphasizing the need for better HCV treatment models. METHODOLOGY: A prospective, multicenter, randomized DETECT HCV clinical trial was conducted at three urban EDs in the US, involving 147,498 adult patients (median age, 41 years; 51.5% men) with diverse racial demographics (42.3% Black, 20.9% Hispanic, and 32.2% White). clinical trial was conducted at three urban EDs in the US, involving 147,498 adult patients (median age, 41 years; 51.5% men) with diverse racial demographics (42.3% Black, 20.9% Hispanic, and 32.2% White). From November 2019 to August 2022, 73,847 patients (50.1%) were randomized to undergo nontargeted HCV screening (HCV testing offered regardless of risk). Among the 73,651 patients (49.9%) randomized to targeted HCV screening (testing offered on the basis of risk assessment), 23,400 (31.8%) were identified as having increased risk. The primary outcome was a newly diagnosed HCV infection with detectable RNA and no known prior HCV diagnosis. Secondary outcomes included repeat diagnoses; HCV test offer, acceptance, and completion rates; HCV genotype and fibrosis staging; components of the HCV care continuum; and 18-month all-cause mortality. TAKEAWAY: Nontargeted screening resulted in significantly more new HCV diagnoses than targeted screening (154 vs 115; relative risk [RR], 1.34; P = .02). Nontargeted HCV screening yielded higher testing rates than targeted screening, with 3.1 times more participants in the nontargeted group being offered testing (89.0% vs 28.5%; P < .001), a higher percentage accepting testing (22.4% vs 9.7%; P < .001), and 2.1 times more participants completing the test (13.4% vs 6.3%; P < .001). Differences in linkage to care remained nonsignificant between the groups (19.5% vs 24.3%; P = .37), with similar rates of treatment initiation (15.6% vs 17.4%; P = .74), treatment completion (12.3% vs 12.2%; P > .99), sustained virologic response at 12 weeks (9.1% vs 9.6%; P > .99), and all-cause mortality at 18 months (5.2% vs 4.3%; P > .99). Among 269 newly diagnosed patients, the 112 (41.6%) with ongoing risk — such as injection drug use — had lower linkage to care (16.1% vs 25.5%; P = .06), lower completion of direct-acting antiviral treatment (5.4% vs 17.2%; P = .004), and lower sustained virologic response (5.4% vs 12.1%; P = .06) than those without recent injection drug use. IN PRACTICE: "This multicenter randomized clinical trial determined a nontargeted screening approach was superior to targeted screening for identifying new HCV infections among patients seen in three urban EDs. The substantial decrease in patients who went from diagnosis to SVR12 [sustained virologic response at 12 weeks] highlights an urgent need for innovative models of HCV treatment," the authors concluded. SOURCE: The study was led by Jason Haukoos, MD, MSc, Department of Emergency Medicine, Denver Health, Denver. It was published online on July 09, 2025, in JAMA. LIMITATIONS: The generalizability of the study outcomes was limited by the inclusion of only three EDs experienced in infectious disease screening. Changes in ED workflows, screening implementation, and the HCV care continuum during the COVID-19 pandemic likely contributed to delays in secondary outcomes. The study was further limited by the exclusion of a large number of ED visits due to high acuity or lack of consent, potential misclassification bias, and the inability to draw clear inferences from the HCV care continuum and secondary outcomes. DISCLOSURES: The study was funded by the National Institute on Drug Abuse. Rothman reported receiving grants from the Gilead Sciences FOCUS program and the Baltimore City Health Department during the conduct of the study. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
